Mark Levine, M.D., M.Sc., F.R.C.P(C)
Dated: July 1, 2007
It is my pleasure to announce the appointment of Dr. Mark Levine as the Chair, Department of Oncology at McMaster University effective July 1, 2007.
Mark Levine is a professor in the Department of Oncology and the Department of Clinical Epidemiology and Biostatistics. He holds the Buffett Taylor Chair in Breast Cancer Research at McMaster University. He is a past recipient of the O. Harold Warwick Prize (1999) from the National Cancer Institute of Canada. Dr. Levine received his medical degree from McGill University and completed his residency in internal medicine at McMaster University. He completed his training in hematology and oncology at Duke University Medical Centre in Durham, North Carolina. In addition, Dr. Levine received a master's degree in clinical epidemiology and biostatistics from McMaster University.
In 1982, Dr. Levine became a member of the Faculty of Health Sciences at McMaster University and a medical oncologist at the Hamilton Regional Cancer Centre (now known as the Juravinski Cancer Centre — Hamilton Health Sciences). He was CEO of the Cancer Centre between 1992 and 1999. Over the past 25 years he has been an active researcher in clinical trials and health services research. His focus is in the areas of breast cancer and venous thromboembolism. A number of the trials he has conducted have impacted on health care in both Canada and internationally. He helped establish the Ontario Clinical Oncology Group (OCOG) in 1982. Dr. Levine has over 220 publications in peer-reviewed journals and has brought much research funding to McMaster. He is Director of the Clinical Trials Methodology Group (CTMG) of the Henderson Research Centre. He was chairman of Health Canada's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Dr. Levine is currently an associate editor for the Journal of Clinical Oncology.
I would also like to take this opportunity to thank Dr. Bill Evans who has been serving as Acting Chair, Department of Oncology since April 1, 2006.